Anavex Life Sciences（AVXL）株式概要
アナベックス・ライフサイエンス社はバイオ製薬会社である。 詳細
AVXL Community Fair Values
Create NarrativeSee what 19 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Anavex Life Sciences Corp. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$2.71 |
| 52週高値 | US$13.99 |
| 52週安値 | US$2.61 |
| ベータ | 1.25 |
| 1ヶ月の変化 | -18.86% |
| 3ヶ月変化 | -38.41% |
| 1年変化 | -63.23% |
| 3年間の変化 | -70.48% |
| 5年間の変化 | -78.30% |
| IPOからの変化 | 3,964.92% |
最新ニュース
Recent updates
新しいナラティブ • Mar 05
Long-Term Neurology Pipeline And Precision Medicine Work Will Support A Stronger Outlook
Catalysts About Anavex Life Sciences Anavex Life Sciences is a clinical stage biopharmaceutical company focused on oral precision medicine therapies for neurological disorders such as early Alzheimer's disease, schizophrenia related conditions, Parkinson's disease, Fragile X syndrome and Rett syndrome. What are the underlying business or industry changes driving this perspective?Seeking Alpha • Feb 10
Anavex: Negative EU Opinion Leaves Blarcamesine In Regulatory Purgatory
Summary Anavex Life Sciences faces regulatory setbacks after the EMA adopted a negative opinion of blarcamesine in Alzheimer's, citing efficacy, safety, and trial design concerns. AVXL's pipeline progress is stalled, with no ongoing clinical trials beyond Compassionate Use and scant details on future development timelines. Financially, the company holds $131.7 million in cash and minimal expenses, providing a multi-year runway but limited near-term catalysts. Given the lack of progress and regulatory limbo, I upgrade AVXL from 'Strong Sell' to 'Sell' as valuation has declined substantially. Read the full article on Seeking Alpha分析記事 • May 21
We're Interested To See How Anavex Life Sciences (NASDAQ:AVXL) Uses Its Cash Hoard To Grow
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Seeking Alpha • Feb 14
Anavex: Looking At Different Statistical Approaches Before EMA Opinion
Summary Anavex Life Sciences Corp.'s stock surged over 50% due to EMA's acceptance of blarcamesine for Alzheimer's review, marking a pivotal moment for the company. Despite mixed trial results, blarcamesine showed significant cognitive improvements, meeting key endpoints, though it failed in functional assessments. Financially, Anavex has a market cap of $720M and a cash runway of 8–10 quarters, with ongoing R&D expenses. Given the EMA review's potential impact, I am considering a small investment, though not right now, acknowledging AVXL stock's high volatility and associated risks. Read the full article on Seeking AlphaSeeking Alpha • Jan 10
The Misconceptions About Anavex Life Sciences' Blarcamesine Phase 2b/3 Trial In Alzheimer's Disease
Summary Anavex Life Sciences' lead drug, Blarcamesine, failed to meet one of the two co-primary endpoints in its phase 2b/3 Alzheimer's trial, casting doubt on its efficacy and approval prospects. The trial's data inconsistencies, significant toxicity, and methodological flaws undermine the drug's potential for regulatory approval by the EMA. Despite a large market potential, the likelihood of approval is low, therefore we argue Anavex's fair valuation is cash basis ($1–$2 per share). Anavex's current financials show it is well-funded, but without successful trials, its future remains bleak. Read the full article on Seeking Alpha分析記事 • Dec 25
We're Interested To See How Anavex Life Sciences (NASDAQ:AVXL) Uses Its Cash Hoard To Grow
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Seeking Alpha • Dec 24
Anavex Life Sciences: Why I Am Still Not Buying The Bull Thesis
Summary Anavex Life Sciences remains one of the few non-amyloid Alzheimer's drug developers, with a market cap just under $1bn and stock up 90% YTD. Other biotech firms in the AD space like Cassava, Annovis, and Alector have faced significant setbacks, including failed trials and financial struggles. Despite my previous “Sell” rating, Anavex stock has shown resilience, up over 350% in five years, and 90% year-to-date, contrasting with peers' declining fortunes. Biogen and Lilly's approved amyloid-targeting drugs have limited efficacy and safety risks, highlighting the need for alternative Alzheimer's treatments like Anavex's approach. Unfortunately, I see too many red flags waving to endorse AVXL, but time will tell — the European approval shot is a major catalyst upcoming that I am bearish on. Read the full article on Seeking AlphaSeeking Alpha • Dec 08
Anavex: EU Approval Application Is A Precipitous Moment
Summary Anavex (AVXL) has submitted an MAA for blarcamesine in Alzheimer's, a critical step that puts their molecule under regulatory scrutiny. Despite past trial failures, Anavex's Phase 2b/3 trial showed significant cognitive improvements, though it failed one co-primary endpoint. Data inconsistencies and lack of US clinical trials raise concerns, but EU approval could still be possible. The EMA's decision on blarcamesine, expected by mid-2025, will be crucial, especially given the FDA's controversial approval of Biogen's Aduhelm. Read the full article on Seeking AlphaSeeking Alpha • Nov 11
Anavex, Cassava Sciences, Panax Ginseng, And The Long-Term Treatment Of Alzheimer's Disease
Summary Panax ginseng shows the highest effectiveness in treating Alzheimer's because it inhibits nitro-oxidative stress, scavenges peroxynitrite, and reverses part of its damage, leading to sustained cognitive improvements over two years. Anavex's Blarcamesine may slow mild Alzheimer's progression due to its antioxidant capacity, with results from a 96-week trial potentially aiding regulatory approval. Cassava Sciences' Simufilam's effectiveness is limited to one year for mild Alzheimer's, with no residual effects after discontinuation, and mixed results in combined mild and moderate groups. Safety profiles differ, with simufilam being safer but less effective long-term compared to blarcamesine. The latter may cause confusion and dizziness. Read the full article on Seeking AlphaSeeking Alpha • Nov 05
Anavex: Understanding Their Latest Alzheimer's Data News With Caution
Summary On Thursday, Oct. 31, Anavex announced new data from their phase 2b/3 Alzheimer's trial, which was presented at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 conference. This news sent the stock soaring, with an ~16% increase in price. I take a look at the new data and share my thoughts here. Read the full article on Seeking AlphaSeeking Alpha • Oct 08
Anavex Stock: A Risky Bet On CNS Drug Development (Rating Downgrade)
Summary Anavex's lead drug, ANAVEX2-73, failed its Phase 2/3 trial for Rett syndrome, and Alzheimer's data showed questionable efficacy and concerning safety issues. The company's financial health is stable with a cash runway of about four years, but operational risks and rising costs are significant concerns. AVXL's decision to seek EU approval for ANAVEX2-73 based on limited data is perplexing, especially given the stringent regulatory environment. The overall recommendation is a "strong sell" due to poor clinical results, overvaluation, and high operational and financial risks. Read the full article on Seeking AlphaSeeking Alpha • Jul 29
Anavex Life Sciences: Short-Lived Spike On Latest Alzheimer's Data Not Surprising
Summary Anavex Life Sciences shared latest data from its SIGMAR-protein targeting drug Blarcamesine yesterday, in Alzheimer's Disease. On a positive note, data showed clinical decline was slowed by 38.5% in the 50-mg arm, and 34.6% in the 30mg arm. On the negative side, the secondary endpoint was not met, and there was a seemingly high number of study withdrawals. Anavex wants to file for approval of Blarcamesine in Europe this year, and also with the FDA in the US. My suspicion is that the FDA will insist on further studies, and EMA may not be convinced on efficacy and safety. Read the full article on Seeking Alpha分析記事 • Jul 17
Companies Like Anavex Life Sciences (NASDAQ:AVXL) Are In A Position To Invest In Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...分析記事 • Apr 01
Here's Why We're Not Too Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...分析記事 • Sep 19
Here's Why We're Not At All Concerned With Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...株主還元
| AVXL | US Biotechs | US 市場 | |
|---|---|---|---|
| 7D | 1.5% | 2.9% | 2.5% |
| 1Y | -63.2% | 33.0% | 26.4% |
業界別リターン: AVXL過去 1 年間で33 % の収益を上げたUS Biotechs業界を下回りました。
リターン対市場: AVXLは、過去 1 年間で26.4 % のリターンを上げたUS市場を下回りました。
価格変動
| AVXL volatility | |
|---|---|
| AVXL Average Weekly Movement | 13.1% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.1% |
安定した株価: AVXLの株価は、 US市場と比較して過去 3 か月間で変動しています。
時間の経過による変動: AVXLの weekly volatility ( 13% ) は過去 1 年間安定していますが、依然としてUSの株式の 75% よりも高くなっています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 2004 | 34 | Terrie Kellmeyer | www.anavex.com |
アナベックス・ライフサイエンシズ社はバイオ医薬品会社である。アルツハイマー病、パーキンソン病、統合失調症、神経発達、神経変性、レット症候群を含む希少疾患、その他の中枢神経系（CNS）障害、疼痛、各種癌に対する革新的な治療法の開発に取り組んでいる。同社の主要な新薬候補であるANAVEX 2-73（ブラルカメシン）は、アルツハイマー病を対象としたフェーズ2aおよびフェーズ2b/3の臨床試験、パーキンソン病認知症を対象としたフェーズ2の概念実証試験、成人患者を対象としたフェーズ2およびフェーズ3の臨床試験、レット症候群の小児患者を対象としたフェーズ2/3の臨床試験を完了した。ANAVEX 2-73は、SIGMAR1およびムスカリン受容体を標的とすることにより、細胞の恒常性を回復させる経口投与可能な薬剤候補である。また、ANAVEX 2-73は動物モデルにおいて抗痙攣作用、抗健忘作用、神経保護作用、抗うつ作用を示し、てんかんを含む中枢神経系疾患の治療薬としての可能性を示している。SIGMAR1およびM1ムスカリン受容体を標的とする同社のANAVEX 3-71は、トランスジェニック（3xTg-AD）マウスにおいて、認知障害、アミロイド、タウ病態を含むアルツハイマー病に対する疾患修飾活性を示す臨床段階の新薬候補である。アナベックス・ライフサイエンス社は2004年に設立され、ニューヨーク州ニューヨークに本社を置いている。
Anavex Life Sciences Corp. 基礎のまとめ
| AVXL 基礎統計学 | |
|---|---|
| 時価総額 | US$249.75m |
| 収益（TTM） | -US$39.95m |
| 売上高(TTM) | n/a |
0.0x
P/Sレシオ-6.3x
PER（株価収益率AVXL は割高か？
公正価値と評価分析を参照収益と収入
| AVXL 損益計算書（TTM） | |
|---|---|
| 収益 | US$0 |
| 売上原価 | US$0 |
| 売上総利益 | US$0 |
| その他の費用 | US$39.95m |
| 収益 | -US$39.95m |
直近の収益報告
Dec 31, 2025
次回決算日
該当なし
| 一株当たり利益（EPS） | -0.43 |
| グロス・マージン | 0.00% |
| 純利益率 | 0.00% |
| 有利子負債／自己資本比率 | 0% |
AVXL の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/26 10:57 |
| 終値 | 2026/05/26 00:00 |
| 収益 | 2025/12/31 |
| 年間収益 | 2025/09/30 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Anavex Life Sciences Corp. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。9
| アナリスト | 機関 |
|---|---|
| Caroline Palomeque | Berenberg |
| Yun Zhong | Brean Capital Historical (Janney Montgomery) |
| Jason Kolbert | D. Boral Capital LLC. |